These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26890290)

  • 1. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
    Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin and everolimus in neuroendocrine tumours: A synergic effect?
    Hue-Fontaine L; Lemelin A; Forestier J; Raverot G; Milot L; Robinson P; Borson-Chazot F; Lombard-Bohas C; Walter T
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):954-960. PubMed ID: 32146090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and pancreatic cancer: a clue requiring investigation.
    Pollak M
    Clin Cancer Res; 2012 May; 18(10):2723-5. PubMed ID: 22465829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
    Vitali E; Boemi I; Piccini S; Tarantola G; Smiroldo V; Lavezzi E; Brambilla T; Zerbi A; Carnaghi C; Mantovani G; Spada A; Lania AG
    Mol Cell Endocrinol; 2020 Jun; 509():110803. PubMed ID: 32251713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
    Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
    Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
    Burney S; Khawaja KI; Saif MW; Masud F
    JOP; 2014 Jul; 15(4):313-6. PubMed ID: 25076330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
    Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
    J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N; Reidy-Lagunes D
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
    Bainbridge HE; Larbi E; Middleton G
    Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
    De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G
    J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.
    Gallo M; Malandrino P; Fanciulli G; Rota F; Faggiano A; Colao A;
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1209-1224. PubMed ID: 28405826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
    Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
    Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.